# Auscom Biopharmaceutical (Haimen) Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/auscom-biopharmaceutical-haimen-co

- Industry: Biotechnology
- Headquarters: Linjiang, China
- Website: www.tobiopharm.com
- Total disclosed funding: $110M
- Latest round: Series B (Jul 24, 2020)
- Investors on record: 12

## About

Auscom Biopharmaceutical (Haimen) Co., Ltd. specializes in biopharmaceutical development, offering innovative solutions and products that enhance efficiency in drug manufacturing processes for the biotech industry.Established in 2017, Auscom Biopharmaceutical (Haimen) Co., Ltd. operates in Linjiang, China. The company focuses on providing integrated CMC solutions for the biopharmaceutical sector. In July 2020, they raised CNY 450 million in Series B funding, co-led by China International Capital Corporation and CITIC Goldstone Fund Management, among others. The firm has completed 3 deals, with the latest funding round totaling CNY 450 million, marking a significant financial milestone for their operations.Auscom Biopharmaceutical specializes in integrated CMC (Chemistry, Manufacturing, and Control) solutions for the biopharmaceutical industry. Their diverse product range includes disposable bioreactors in sizes such as 50L, 200L, 500L, and 2000L, as well as customized coupling reactors and advanced ADC (Antibody-Drug Conjugate) development services. These offerings are designed to provide flexibility and high efficiency in biopharmaceutical production, catering to clients across North America, Europe, and Asia.Auscom Biopharmaceutical generates revenue through a structure that includes partnerships and B2B transactions with pharmaceutical companies. They offer bespoke solutions, including their proprietary MeCHOta® process development and comprehensive quality management systems, engaging clients in contract agreements that span multiple phases of production, from early-stage development to GMP (Good Manufacturing Practice) compliant production.Following their recent Series B funding round in July 2020, Auscom Biopharmaceutical plans to leverage the CNY 450 million raised to develop new products and expand into additional markets. The company aims to enhance their product offerings and explore opportunities in emerging regions within Asia and Europe over the next few years. This strategic funding will support product development initiatives and facilitate entry into these targeted markets.

## Funding rounds

- Series B, Jul 24, 2020, $65M — China International Capital Corporation, CCB International, CITIC Goldstone Fund Management, Wens Capital, Shanghai Huaxu Investment
- Series A, Jan 2, 2019, $45M — Beyond Capital, New Alliance Capital, Addor Capital, Jilin Aodong Pharmaceutical Group Co., Ltd, Blue Bay Capital, Tenyall & Sumin, Tenykin Capital

## Investors

- Beyond Capital — Series A
- New Alliance Capital (https://capitalatlas.ai/funds/new-alliance-capital) — Series A
- Addor Capital (https://capitalatlas.ai/funds/addor-capital) — Series A
- Jilin Aodong Pharmaceutical Group Co., Ltd — Series A
- Blue Bay Capital — Series A
- Tenyall & Sumin — Series A
- Tenykin Capital (https://capitalatlas.ai/funds/tenykin-capital) — Series A
- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series B
- CCB International (https://capitalatlas.ai/funds/ccb-international) — Series B
- CITIC Goldstone Fund Management (https://capitalatlas.ai/funds/citic-goldstone-fund-management) — Series B
- Wens Capital (https://capitalatlas.ai/funds/wens-capital) — Series B
- Shanghai Huaxu Investment — Series B